Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
Treatment with FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) can be effective, but it has serious side effects, which may require hospitalization.

The purpose of this study is to investigate whether the addition of tocotrienol can reduce the side effects to FOLFOXIRI otherwise leading to hospitalization.
Colorectal Cancer
DRUG: Irinotecan 165 mg/m2 iv|DRUG: Oxaliplatin 85 mg/m2 iv|DRUG: Calcium folinate 200 mg/m2 iv|DRUG: 5-fluorouracil 3200 mg/m2|DIETARY_SUPPLEMENT: Tocotrienol|DRUG: Placebo
Time to first serious adverse event, 6 months after the last patient has finished chemotherapy
Number of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy, 6 months after the last patient has finished chemotherapy|Duration of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy, 6 months after the last patient has finished chemotherapy|Death during treatment calculated from date of first treatment until 1 month after completed chemotherapy, 6 months after the last patient has finished chemotherapy|Response rate, 6 months after the last patient has finished chemotherapy|Progression free survival, 6 months after the last patient has finished chemotherapy|Overall survival, 6 months after the last patient has finished chemotherapy|Number of patients with treatment related adverse events as assessed by CTCAE v.4.0, 6 months after the last patient has finished chemotherapy|Quality of life as measured by combined questionnaire consisting of EORTC QLQ-C30 and CR29, 6 months after the last patient has finished chemotherapy|Resection rate, 6 months after the last patient has finished chemotherapy
Treatment with FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) can be effective, but it has serious side effects, which may require hospitalization.

The purpose of this study is to investigate whether the addition of tocotrienol can reduce the side effects to FOLFOXIRI otherwise leading to hospitalization.